Jane Street Group LLC Boosts Stock Position in Exscientia plc (NASDAQ:EXAI)

Jane Street Group LLC increased its position in shares of Exscientia plc (NASDAQ:EXAI) by 601.7% during the 3rd quarter, Holdings Channel reports. The firm owned 290,154 shares of the company’s stock after acquiring an additional 248,805 shares during the period. Jane Street Group LLC’s holdings in Exscientia were worth $1,416,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of EXAI. Novo Holdings A S bought a new stake in Exscientia during the 2nd quarter valued at approximately $66,742,000. Bank of New York Mellon Corp lifted its holdings in shares of Exscientia by 108.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company’s stock valued at $1,981,000 after acquiring an additional 202,377 shares during the last quarter. Olympiad Research LP purchased a new position in Exscientia in the third quarter worth about $448,000. Susquehanna Fundamental Investments LLC purchased a new stake in Exscientia during the 2nd quarter valued at $256,000. Finally, Federated Hermes Inc. purchased a new position in shares of Exscientia during the 2nd quarter worth about $115,000. Hedge funds and other institutional investors own 41.58% of the company’s stock.

Exscientia Price Performance

Shares of EXAI stock opened at $4.84 on Friday. The stock has a 50 day moving average price of $4.97 and a 200 day moving average price of $5.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.54 and a current ratio of 4.54. The firm has a market capitalization of $632.93 million, a P/E ratio of -3.21 and a beta of 0.83. Exscientia plc has a 52-week low of $3.80 and a 52-week high of $7.91.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.